NO20032387D0 - Kombinasjon av GABA agonister og aldose reduktase inhibitorer - Google Patents

Kombinasjon av GABA agonister og aldose reduktase inhibitorer

Info

Publication number
NO20032387D0
NO20032387D0 NO20032387A NO20032387A NO20032387D0 NO 20032387 D0 NO20032387 D0 NO 20032387D0 NO 20032387 A NO20032387 A NO 20032387A NO 20032387 A NO20032387 A NO 20032387A NO 20032387 D0 NO20032387 D0 NO 20032387D0
Authority
NO
Norway
Prior art keywords
combination
reductase inhibitors
aldose reductase
gaba agonists
gaba
Prior art date
Application number
NO20032387A
Other languages
English (en)
Other versions
NO20032387L (no
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20032387L publication Critical patent/NO20032387L/no
Publication of NO20032387D0 publication Critical patent/NO20032387D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20032387A 2000-11-30 2003-05-27 Kombinasjon av GABA agonister og aldose reduktase inhibitorer NO20032387D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25044800P 2000-11-30 2000-11-30
PCT/IB2001/002214 WO2002043763A2 (en) 2000-11-30 2001-11-19 Combination of gaba agonists and aldose reductase inhibitors

Publications (2)

Publication Number Publication Date
NO20032387L NO20032387L (no) 2003-05-27
NO20032387D0 true NO20032387D0 (no) 2003-05-27

Family

ID=22947799

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032387A NO20032387D0 (no) 2000-11-30 2003-05-27 Kombinasjon av GABA agonister og aldose reduktase inhibitorer

Country Status (34)

Country Link
US (1) US6720348B2 (no)
EP (1) EP1337272A2 (no)
JP (1) JP2004514700A (no)
KR (1) KR20030059287A (no)
CN (1) CN1477976A (no)
AP (1) AP2001002359A0 (no)
AR (1) AR031432A1 (no)
AU (1) AU2002215160A1 (no)
BG (1) BG107812A (no)
BR (1) BR0115776A (no)
CA (1) CA2430309A1 (no)
CR (1) CR6962A (no)
CZ (1) CZ20031387A3 (no)
DO (1) DOP2001000294A (no)
EA (1) EA200300433A1 (no)
EC (1) ECSP034629A (no)
EE (1) EE200300249A (no)
HR (1) HRP20030419A2 (no)
HU (1) HUP0302555A3 (no)
IL (1) IL155710A0 (no)
IS (1) IS6787A (no)
MA (1) MA26965A1 (no)
MX (1) MXPA03004871A (no)
NO (1) NO20032387D0 (no)
OA (1) OA12413A (no)
PA (1) PA8534201A1 (no)
PE (1) PE20020598A1 (no)
PL (1) PL365378A1 (no)
SK (1) SK6092003A3 (no)
SV (1) SV2003000752A (no)
TN (1) TNSN01170A1 (no)
UY (1) UY27044A1 (no)
WO (1) WO2002043763A2 (no)
ZA (1) ZA200303340B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6696407B1 (en) * 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US20030162754A1 (en) * 2001-12-17 2003-08-28 Tufts University Use of GABA and GABAB agonists
AU2003243603A1 (en) * 2002-06-13 2003-12-31 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
EP1572173B1 (en) * 2002-12-13 2010-04-28 Warner-Lambert Company LLC Alpha-2-delta ligand to treat lower urinary tract symptoms
US20080318908A1 (en) * 2002-12-17 2008-12-25 Trustees Of Tufts College Use of gaba and gabab agonists
EP1480631B1 (en) * 2002-12-20 2007-08-01 Dynogen Pharmaceuticals Inc. Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators
WO2004084879A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
CA2625210A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2007236115A1 (en) 2006-04-11 2007-10-18 Novartis Ag Organic compounds
EP2124913A1 (en) * 2006-12-22 2009-12-02 Novartis AG 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
DK2326632T3 (en) * 2008-09-06 2017-09-18 Bionevia Pharmaceuticals Inc New choline crystal of epalrestate
AU2011348074B2 (en) 2010-12-23 2016-04-28 The Board Of Regents Of The University Of Texas System Methods for treating COPD
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN107847548B (zh) * 2015-05-18 2022-06-14 贝思以色列女会吏医学中心公司 P物质、肥大细胞脱颗粒抑制剂和周围神经病
EA201992515A1 (ru) * 2017-04-21 2020-04-09 Стивен Хоффман Композиции и способы для лечения ретинопатии
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
US4130714A (en) 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
HU182086B (en) 1979-06-01 1983-12-28 Wellcome Found Process for preparing new 1,2,4-triazine derivatives
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative
US4791126A (en) 1980-08-22 1988-12-13 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
CA1176269A (en) 1981-03-02 1984-10-16 Kazimir Sestanj N-naphthoylglycine derivatives
US4436745A (en) 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5066659A (en) 1984-10-30 1991-11-19 Pfizer Inc. Spiro-heteroazalones for treatment of diabetic complications
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
AU602641B2 (en) 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use
EP0264586B1 (en) 1986-08-28 1991-04-03 Sanwa Kagaku Kenkyusho Co., Ltd. Hydantoin derivatives for treating complications of diabetes
US4771052A (en) * 1987-02-05 1988-09-13 Hoechst-Roussel Pharmaceuticals, Inc. Tetrahydropyrido[3',4':4,5]pyrrolo[2,3-c]quinolines and their use as hypotensive agents
GB8801037D0 (en) 1988-01-18 1988-02-17 Plessey Co Ltd Improvements relating to fuel supply systems
US5252572A (en) * 1988-02-03 1993-10-12 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4980357A (en) 1990-03-01 1990-12-25 Pfizer Inc. Azolidinedione derivatives
US5037831A (en) 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
AU683620B2 (en) * 1992-09-28 1997-11-20 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
EP1041068B1 (en) * 1999-04-01 2004-04-14 Pfizer Products Inc. Compounds for treating and preventing diabetic complications
US6583172B1 (en) * 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders

Also Published As

Publication number Publication date
CZ20031387A3 (cs) 2004-04-14
PL365378A1 (en) 2005-01-10
NO20032387L (no) 2003-05-27
HUP0302555A3 (en) 2005-06-28
BR0115776A (pt) 2004-01-13
PA8534201A1 (es) 2002-10-24
SV2003000752A (es) 2003-01-13
IL155710A0 (en) 2003-11-23
WO2002043763A3 (en) 2003-03-13
EA200300433A1 (ru) 2003-10-30
CA2430309A1 (en) 2002-06-06
US6720348B2 (en) 2004-04-13
BG107812A (bg) 2004-02-27
CN1477976A (zh) 2004-02-25
CR6962A (es) 2004-02-02
ZA200303340B (en) 2004-04-30
JP2004514700A (ja) 2004-05-20
AR031432A1 (es) 2003-09-24
IS6787A (is) 2003-04-14
PE20020598A1 (es) 2002-07-08
OA12413A (en) 2004-09-30
MA26965A1 (fr) 2004-12-20
AP2001002359A0 (en) 2001-12-31
HRP20030419A2 (en) 2004-08-31
AU2002215160A1 (en) 2002-06-11
MXPA03004871A (es) 2003-08-19
EP1337272A2 (en) 2003-08-27
WO2002043763A2 (en) 2002-06-06
ECSP034629A (es) 2003-07-25
US20020077319A1 (en) 2002-06-20
EE200300249A (et) 2003-10-15
KR20030059287A (ko) 2003-07-07
HUP0302555A2 (hu) 2003-11-28
SK6092003A3 (en) 2004-07-07
UY27044A1 (es) 2002-07-31
TNSN01170A1 (fr) 2005-11-10
DOP2001000294A (es) 2002-08-30

Similar Documents

Publication Publication Date Title
NO20032387L (no) Kombinasjon av GABA agonister og aldose reduktase inhibitorer
EE200300470A (et) Aldoosreduktaasi püridasinooninhibiitorid
NO20032441D0 (no) Kombinasjon av GABA agonister og sorbitol-dehydrogenase inhibitorer
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20033491D0 (no) Heterocykliske inhibitorer av ERK2 og anvendelser derav
DE60319430D1 (de) R- und fgfr-inhibitoren
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
ITMI20021391A0 (it) Nitroderivati di inibitori della cicloossigenasi-2
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
NO20020326L (no) Sammensetning og anvendelse av en inhibitor av PPAR-delta-aktivitet
IL156776A0 (en) Inhibitors of cruzipain and other cysteine proteases
IL157935A0 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
DK1337271T3 (da) Kombination af GABA-agonister og sorbitoldehydrogenaseinhibitorer
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat
SI1337271T1 (en) Combination of gaba agonists and sorbitol dehydrogenase inhibitors
NO20024452A (no) Anordning og fremgangsmåte ved lineskive
NO20001435D0 (no) Fremgangsmåte for bestemmelse av CMT1A og HNPP
SE0004239D0 (sv) New use of an inhibitor
IT1315009B1 (it) Procedimento di rilevazione e visualizzazione di temperatura adadattamento dinamico e relativo dispositivo.
AU2002219398A1 (en) Inhibitors of cruzipain and other cysteine proteases
ZA200305260B (en) Inhibitors of cruzipain and other cysteine proteases.
ZA200305259B (en) Inhibitors of cruzipain and other cysteine proteases.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application